Galderma previews its 2026 EADV research agenda, spanning dermatoporosis, sensitive skin, and cellular senescence. Learn what this means for skin longevity.
In September 2026, Galderma announced its planned scientific presentations for the European Academy of Dermatology and Venereology Congress in Vienna. The company stated it would present 19 abstracts, including two oral presentations, between September 30 and October 3. The announced program covers a wide spectrum of clinical and cosmetic dermatology. The research agenda spans sensitive skin, dermatoporosis, acne, skin barrier function, and skin longevity.
Galderma's Head of Global Medical Affairs, Bill Andriopoulos, noted that the program addresses both chronic skin conditions and emerging research areas. He described the overall aim of the presentations as supporting meaningful outcomes for patients. Practical Dermatology independently summarized the planned abstracts. Their report highlighted the focus on long-term data, sensitive skin research, and novel acne presentations.
The core of the announced research bridges the gap between chronic skin diseases and the natural processes of tissue aging. One major focus is dermatoporosis, a condition characterised by extreme skin fragility in older adults. Galderma scheduled a presentation on the clinical signs and symptoms of dermatoporosis specifically in individuals aged 65 and older. A separate presentation focuses on the underlying biomarkers associated with aging in mature, fragile skin.
Another focal point of the program is the management of long-term skin conditions and their impact on skin resilience. The company announced a presentation of ARCADIA open-label extension data concerning the medication nemolizumab. This research assesses safety and efficacy through 152 weeks in adults and adolescents with moderate-to-severe atopic dermatitis. Galderma also planned a post-hoc analysis examining nemolizumab safety over two years for patients with atopic dermatitis and prurigo nodularis.
Beyond chronic disease, the program includes research on everyday skin barrier function and cosmetic interventions. Galderma announced a prospective, baseline-controlled study evaluating a gentle cleanser and barrier-restoring moisturizer regimen. This routine was studied in people with mild-to-moderate atopic dermatitis to assess biophysical, clinical, and quality-of-life outcomes. Additional skin health topics include incorporating antioxidants for daytime defense and nighttime repair.
The company also announced studies focusing on topical formulations and acne management. A scheduled presentation covers a triple-acid topical formulation and its effects on hydration and barrier function. For acne, presentations cover a hydrocolloid patch for pustules and the use of trifarotene for redness and color evenness. The company also announced laboratory research involving human keratinocytes. This specific study tests a lysine-based dendritic polymer with niacinamide for acne-related inflammation.
The intersection of these distinct fields is highlighted by an announced Industry Expert Hub session. This educational event focuses on targeting cellular senescence in relation to skin aging, dermatoporosis, and skin longevity. By studying how aging cells behave, researchers hope to better understand how cellular changes translate into visible structural weakness over time. Understanding these mechanisms is a key part of using evidence-based topical ingredients effectively.
While the breadth of the planned presentations is substantial, it is crucial to view this announcement as a preview of research. The initial communication describes planned studies but does not provide the detailed outcomes required to judge efficacy. Without published sample sizes, confidence intervals, or specific outcome percentages, the clinical relevance of the findings remains unverified. Readers must separate the concept of a topic being studied from a treatment being definitively shown to work.
The methodologies behind the 19 abstracts also vary significantly. Some of the named work is explicitly early-stage, such as the acne inflammation presentation concerning human keratinocytes in a laboratory setting. Other entries rely on cross-sectional analysis, retrospective image analysis, or post-hoc trial analyses. These specific research designs provide valuable insights but are not equivalent to prospective clinical trials demonstrating clear patient benefit.
Furthermore, the specific populations studied must be kept in clear context when interpreting the eventual data. The dermatoporosis study on signs and symptoms specifically observes participants aged 65 and over. This distinct demographic should not be conflated with the broader audience of women aged 30 to 60 who are building preventative routines. Finally, the Industry Expert Hub session on cellular senescence is a scheduled educational event, not independent proof that a specific product reverses cellular aging.
This research preview offers practical reminders for health-conscious women building a long-term skincare routine. The heavy focus on gentle cleansers and barrier-restoring moisturizers reinforces the importance of foundational skin health. You do not need to wait for advanced biomarker research to start protecting your skin barrier today. Consistently using gentle, hydrating products is vital for managing sensitive and fragile skin types.
The upcoming presentations also highlight how chronic inflammation, whether from acne or environmental stress, impacts long-term resilience. Using targeted formulations for daytime defense can help mitigate some of this daily wear and tear. For those dealing with persistent sensitivity, a focused approach to barrier care is often more effective than chasing trendy new active ingredients. Focus on maintaining a robust barrier rather than aggressively exfoliating or stripping the skin.
Ultimately, the announced research underscores that maintaining skin resilience is a complex, long-term process. It involves addressing daily hydration, managing underlying inflammation, and understanding how the skin structurally changes with age. By adopting a comprehensive approach that prioritises barrier function and gentle care, you can support your skin through every phase of life. This is the foundation of building a consistent routine for skin longevity.
Remember that a preview of upcoming research is not a substitute for personalised medical advice. For persistent acne, severe sensitivity, or rapid changes in skin fragility, always consult a qualified dermatologist. Early-stage clinical abstracts can guide future product development, but they do not replace the tailored guidance of a healthcare professional. Health-conscious consumers should prioritize proven foundational care while waiting for emerging science to be fully validated.
As dermatology continues to bridge the gap between chronic disease management and proactive skin longevity, our understanding of tissue resilience will only deepen. The focus on cellular senescence and mature skin biomarkers suggests a future where interventions might be tailored to specific stages of cellular aging. Will the next generation of dermatological research allow us to identify and support vulnerable skin long before the clinical signs of dermatoporosis ever appear?
Stay connected for research and practical guidance on skin, hair, collagen, nutrition and beauty longevity. Clear ideas for people who want to understand how appearance changes with age and make better-informed choices over time.
Understand your skin, hair and body better without chasing every new trend, treatment or promise.
explore the Blog
